|
EP0022229B1
(en)
*
|
1979-06-29 |
1982-12-08 |
The Wellcome Foundation Limited |
Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof
|
|
GR76950B
(enExample)
|
1980-12-18 |
1984-09-04 |
Wellcome Found |
|
|
AU576322B2
(en)
|
1983-07-22 |
1988-08-25 |
Ici Australia Limited |
Alpha-substituted-alpha-cyanomethyl alcohols
|
|
US4783443A
(en)
|
1986-03-03 |
1988-11-08 |
The University Of Chicago |
Amino acyl cephalosporin derivatives
|
|
JPH05255106A
(ja)
|
1990-10-31 |
1993-10-05 |
Toray Ind Inc |
血小板減少症治療剤
|
|
JPH059164A
(ja)
|
1991-07-02 |
1993-01-19 |
Sumitomo Chem Co Ltd |
光学活性マンデロニトリル誘導体の製造方法
|
|
GB9217331D0
(en)
|
1992-08-14 |
1992-09-30 |
Xenova Ltd |
Pharmaceutical compounds
|
|
US5872151A
(en)
|
1992-10-01 |
1999-02-16 |
Glaxo Wellcome Inc. |
Immunopotentiatory agents and physiologically acceptable salts thereof
|
|
ES2096215T3
(es)
*
|
1992-10-01 |
1997-03-01 |
Wellcome Found |
Tucaresol como agente inmunopotenciador.
|
|
US6096786A
(en)
*
|
1992-10-01 |
2000-08-01 |
Glaxo Wellcome Inc. |
Immunopotentiatory agent and physiologically acceptable salts thereof
|
|
ES2224200T3
(es)
|
1992-11-27 |
2005-03-01 |
Mayne Pharma (Usa) Inc. |
Composicion inyectable estable de paclitaxel.
|
|
JPH0725858A
(ja)
|
1993-07-13 |
1995-01-27 |
Otsuka Pharmaceut Co Ltd |
ピペラジン誘導体
|
|
US5958980A
(en)
|
1993-08-26 |
1999-09-28 |
Glaxo Wellcome, Inc. |
Immunopotentiatory agent and physiologically acceptable salts thereof
|
|
IL110787A0
(en)
|
1993-08-27 |
1994-11-11 |
Sandoz Ag |
Biodegradable polymer, its preparation and pharmaceutical composition containing it
|
|
GB9402809D0
(en)
|
1994-02-14 |
1994-04-06 |
Xenova Ltd |
Pharmaceutical compounds
|
|
GB9402807D0
(en)
|
1994-02-14 |
1994-04-06 |
Xenova Ltd |
Pharmaceutical compounds
|
|
GB9426224D0
(en)
|
1994-12-23 |
1995-02-22 |
Xenova Ltd |
Pharmaceutical compounds
|
|
US5891877A
(en)
|
1995-02-14 |
1999-04-06 |
Xenova Limited |
Pharmaceutical compounds
|
|
US5874443A
(en)
|
1995-10-19 |
1999-02-23 |
Trega Biosciences, Inc. |
Isoquinoline derivatives and isoquinoline combinatorial libraries
|
|
US5886210A
(en)
|
1996-08-22 |
1999-03-23 |
Rohm And Haas Company |
Method for preparing aromatic compounds
|
|
JP3131574B2
(ja)
|
1996-09-04 |
2001-02-05 |
新日本製鐵株式会社 |
新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
|
|
US5939098A
(en)
|
1996-09-19 |
1999-08-17 |
Schering Corporation |
Cancer treatment with temozolomide
|
|
US5922683A
(en)
|
1997-05-29 |
1999-07-13 |
Abbott Laboratories |
Multicyclic erythromycin derivatives
|
|
AUPO735997A0
(en)
|
1997-06-17 |
1997-07-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Piperazine derivatives
|
|
ES2352739T3
(es)
|
1997-11-21 |
2011-02-22 |
Purdue Neuroscience Company |
2-aminoacetamidas sustituidas y el uso de las mismas.
|
|
CN1173946C
(zh)
|
1998-01-29 |
2004-11-03 |
阿温蒂斯药物公司 |
制备n-[(脂族或芳族)羰基]-2-氨基乙酰胺化合物和环化化合物的方法
|
|
US7141603B2
(en)
|
1999-02-19 |
2006-11-28 |
The Regents Of The University California |
Antitumor agents
|
|
US6069146A
(en)
|
1998-03-25 |
2000-05-30 |
The Regents Of The University Of California |
Halimide, a cytotoxic marine natural product, and derivatives thereof
|
|
EP1069111A4
(en)
|
1998-03-26 |
2001-06-06 |
Shionogi & Co |
INDOLE DERIVATIVES EXER ANT ANTIVIRAL ACTIVITY
|
|
US6509331B1
(en)
|
1998-06-22 |
2003-01-21 |
Elan Pharmaceuticals, Inc. |
Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
|
|
GB9818627D0
(en)
|
1998-08-26 |
1998-10-21 |
Glaxo Group Ltd |
Improvements in dva vaccination
|
|
FR2784988B1
(fr)
|
1998-10-23 |
2002-09-20 |
Adir |
Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US7026322B2
(en)
|
1998-11-12 |
2006-04-11 |
Nereus Pharmaceuticals, Inc. |
Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
|
|
US6358957B1
(en)
|
1998-11-12 |
2002-03-19 |
Nereus Pharmaceuticals, Inc. |
Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
|
|
PT1210428E
(pt)
|
1999-08-23 |
2015-07-21 |
Genetics Inst Llc |
Pd-1, um recetor para b7-4 e suas utilizações
|
|
MXPA02001878A
(es)
|
1999-08-23 |
2003-08-20 |
Dana Farber Cancer Inst Inc |
Moleculas b7-4 novedosas y usos de las mismas.
|
|
EP1234031B2
(en)
|
1999-11-30 |
2021-11-24 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
|
CA2403790C
(en)
|
2000-01-18 |
2011-09-27 |
Nereus Pharmaceuticals, Inc. |
A cell division inhibitor and a production method thereof
|
|
EP1265840A2
(en)
|
2000-03-17 |
2002-12-18 |
Corixa Corporation |
Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
|
|
JP5101781B2
(ja)
|
2000-05-09 |
2012-12-19 |
アンギオアールエックス コーポレイション |
ピペラジンジオン化合物
|
|
JP2004518731A
(ja)
|
2000-12-28 |
2004-06-24 |
ニューロクライン バイオサイエンシーズ， インコーポレイテッド |
三環式ｃｒｆレセプターアンタゴニスト
|
|
US20030082140A1
(en)
|
2001-08-20 |
2003-05-01 |
Fisher Paul B. |
Combinatorial methods for inducing cancer cell death
|
|
WO2003074550A2
(en)
|
2002-03-01 |
2003-09-12 |
Pintex Pharmaceuticals, Inc. |
Pin1-modulating compounds and methods of use thereof
|
|
RS96304A
(sr)
|
2002-05-17 |
2006-10-27 |
Aventis Pharma S.A. |
Primena docetaksel/doksorubicin/ ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika
|
|
US7012100B1
(en)
|
2002-06-04 |
2006-03-14 |
Avolix Pharmaceuticals, Inc. |
Cell migration inhibiting compositions and methods and compositions for treating cancer
|
|
DE60316688T2
(de)
|
2002-08-02 |
2008-07-17 |
Nereus Pharmaceuticals, Inc., San Diego |
Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
|
|
US7935704B2
(en)
|
2003-08-01 |
2011-05-03 |
Nereus Pharmaceuticals, Inc. |
Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
|
|
US7919497B2
(en)
|
2002-08-02 |
2011-04-05 |
Nereus Pharmaceuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
SE0202429D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel Compounds
|
|
WO2004056875A1
(en)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
US20040197312A1
(en)
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
WO2005077940A1
(en)
|
2004-02-04 |
2005-08-25 |
Nereus Pharmaceuticals, Inc. |
Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
|
|
PL1740593T3
(pl)
|
2004-04-19 |
2016-09-30 |
|
Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I
|
|
PL2161336T5
(pl)
*
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
CA2612241C
(en)
|
2005-07-01 |
2018-11-06 |
Medarex, Inc. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
|
WO2007035841A1
(en)
|
2005-09-21 |
2007-03-29 |
Nereus Pharmaceuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
AU2007207465B2
(en)
|
2006-01-18 |
2012-12-06 |
Merck Patent Gmbh |
Specific therapy using integrin ligands for treating cancer
|
|
WO2007113648A2
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
US8129527B2
(en)
|
2006-11-03 |
2012-03-06 |
Nereus Pharmacuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
AU2008216669B2
(en)
*
|
2007-02-15 |
2013-12-12 |
Mannkind Corporation |
A method for enhancing T cell response
|
|
JP5641927B2
(ja)
|
2007-04-13 |
2014-12-17 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
Ｓｐａｒｃ及びその使用方法
|
|
US20090170837A1
(en)
|
2007-08-17 |
2009-07-02 |
Thallion Pharmaceuticals Inc. |
Methods for treating ras driven cancer in a subject
|
|
US8569262B2
(en)
|
2007-11-02 |
2013-10-29 |
Momenta Pharmaceuticals, Inc. |
Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
|
|
KR20100100949A
(ko)
|
2008-01-08 |
2010-09-15 |
브리스톨-마이어스 스큅 컴퍼니 |
증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
|
EP4209510B1
(en)
|
2008-12-09 |
2024-01-31 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
MX2011007583A
(es)
|
2009-01-16 |
2011-12-14 |
Teva Pharma |
Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos.
|
|
WO2010114922A1
(en)
|
2009-03-31 |
2010-10-07 |
Agios Pharmaceuticals, Inc. |
Methods of treating cancer having an aberrant egfr or kras genotype
|
|
GB0907551D0
(en)
|
2009-05-01 |
2009-06-10 |
Univ Dundee |
Treatment or prophylaxis of proliferative conditions
|
|
EP2464218B1
(en)
|
2009-08-10 |
2015-05-27 |
Board of Regents, The University of Texas System |
Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
|
|
CA2939165A1
(en)
|
2009-09-15 |
2011-03-24 |
Cerulean Pharma Inc. |
A cdp-camptothecin conjugate, particle or composition and uses thereof
|
|
WO2011050344A2
(en)
*
|
2009-10-23 |
2011-04-28 |
Mannkind Corporation |
Cancer immunotherapy and method of treatment
|
|
NO2504364T3
(enExample)
|
2009-11-24 |
2018-01-06 |
|
|
|
CN101766815B
(zh)
|
2009-12-31 |
2012-04-25 |
胡松华 |
紫杉醇及多西紫杉醇的用途
|
|
EP2542699A4
(en)
|
2010-03-03 |
2013-10-02 |
Targeted Molecular Diagnostics Llc |
METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
|
|
US20130064831A1
(en)
|
2010-05-17 |
2013-03-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
|
US20130131018A1
(en)
|
2010-06-04 |
2013-05-23 |
Exonhit S.A. |
Substituted isoquinolines and their use as tubulin polymerization inhibitors
|
|
JP2012033526A
(ja)
|
2010-07-28 |
2012-02-16 |
Fuji Electric Co Ltd |
薄膜太陽電池およびその製造方法
|
|
WO2012035436A1
(en)
*
|
2010-09-15 |
2012-03-22 |
Tokyo University Of Pharmacy And Life Sciences |
Plinabulin prodrug analogs and therapeutic uses thereof
|
|
WO2012074904A2
(en)
|
2010-11-29 |
2012-06-07 |
Precision Therapeutics, Inc. |
Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
|
|
TWI386203B
(zh)
|
2011-01-07 |
2013-02-21 |
Univ China Medical |
治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
|
|
SI2699264T1
(en)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
WO2013078537A1
(en)
|
2011-11-28 |
2013-06-06 |
National Research Council Of Canada |
Paclitaxel response markers for cancer
|
|
US20150004175A1
(en)
|
2011-12-13 |
2015-01-01 |
Yale University |
Compositions and Methods for Reducing CTL Exhaustion
|
|
BR112014028094B1
(pt)
|
2012-05-09 |
2022-03-03 |
Cantex Pharmaceuticals, Inc |
Uso de um heparinoide interagindo com fator de plaqueta 4
|
|
AU2013204313C1
(en)
|
2012-06-01 |
2016-04-07 |
Bionomics Limited |
Combination Therapy
|
|
US10034939B2
(en)
|
2012-10-26 |
2018-07-31 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
|
LT2958943T
(lt)
|
2013-02-20 |
2020-01-27 |
The Trustees Of The University Of Pennsylvania |
Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
|
|
WO2014160183A1
(en)
|
2013-03-13 |
2014-10-02 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Methods for modulating chemotherapeutic cytotoxicity
|
|
US10809323B2
(en)
|
2013-04-24 |
2020-10-20 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Magnetic resonance maps for analyzing tissue
|
|
CN105658206A
(zh)
|
2013-06-03 |
2016-06-08 |
诺华股份有限公司 |
抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合
|
|
EP3076972B1
(en)
|
2013-10-11 |
2021-10-06 |
BeyondSpring, Inc. |
Cancer treatment with combination of plinabulin and taxane
|
|
IL292510A
(en)
*
|
2013-11-05 |
2022-06-01 |
Cognate Bioservices Inc |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
EP3066215B1
(en)
|
2013-11-06 |
2019-04-24 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Method for subtyping lymphoma types by means of expression profiling
|
|
CN104796448B
(zh)
|
2014-01-22 |
2019-02-12 |
腾讯科技（深圳）有限公司 |
网络系统的数据处理方法和装置
|
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
US10392444B2
(en)
*
|
2014-08-08 |
2019-08-27 |
Oncoquest, Inc. |
Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
|
|
WO2016081281A1
(en)
|
2014-11-17 |
2016-05-26 |
Salk Institute For Biological Studies |
Lipophilic bisphosphonates and methods of use
|
|
KR20240110996A
(ko)
|
2015-02-12 |
2024-07-16 |
비욘드스프링 파마수티컬스, 인코포레이티드. |
면역 관문 저해제와 조합한 플리나불린의 용도
|
|
AU2016229295B2
(en)
|
2015-03-06 |
2021-11-04 |
Beyondspring Pharmaceuticals, Inc. |
Method of treating a brain tumor
|
|
SG10202008673WA
(en)
|
2015-03-06 |
2020-10-29 |
Beyondspring Pharmaceuticals Inc |
Method of treating cancer associated with a ras mutation
|
|
WO2016165007A1
(en)
|
2015-04-17 |
2016-10-20 |
The University Of British Columbia |
Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
|
|
CN106279039B
(zh)
|
2015-06-02 |
2019-01-11 |
青岛海洋生物医药研究院股份有限公司 |
氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
|
|
US10155748B2
(en)
|
2015-07-13 |
2018-12-18 |
Beyondspring Pharmaceuticals, Inc. |
Plinabulin compositions
|
|
WO2017062505A1
(en)
|
2015-10-05 |
2017-04-13 |
Cedars-Sinai Medical Center |
Method of classifying and diagnosing cancer
|
|
JP2019511565A
(ja)
*
|
2016-02-08 |
2019-04-25 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
ツカレゾールまたはそのアナログを含む組成物
|
|
AU2017278245B2
(en)
|
2016-06-06 |
2022-09-15 |
Beyondspring Pharmaceuticals, Inc. |
Composition and method for reducing neutropenia
|
|
EP3565812B1
(en)
|
2017-01-06 |
2023-12-27 |
Beyondspring Pharmaceuticals, Inc. |
Tubulin binding compounds and therapeutic use thereof
|
|
KR20240110997A
(ko)
|
2017-02-01 |
2024-07-16 |
비욘드스프링 파마수티컬스, 인코포레이티드. |
호중구감소증의 감소 방법
|
|
NZ778329A
(en)
|
2017-03-13 |
2026-03-27 |
Beyondspring Pharmaceuticals Inc |
Compositions of plinabulin and use thereof
|
|
US10933061B2
(en)
|
2017-12-21 |
2021-03-02 |
Shepherd Therapeutics, Inc. |
Pyrvinium pamoate therapies and methods of use
|
|
EP3743074A4
(en)
|
2018-01-24 |
2021-12-15 |
Beyondspring Pharmaceuticals Inc. |
COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
|
|
CA3089391A1
(en)
|
2018-02-01 |
2019-08-08 |
Beyondspring Pharmaceuticals, Inc. |
Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent
|
|
CN110240592A
(zh)
|
2018-03-08 |
2019-09-17 |
青岛海洋生物医药研究院股份有限公司 |
(z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用
|
|
CN111936143A
(zh)
|
2018-04-05 |
2020-11-13 |
诺维嘉研究公司 |
用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品
|
|
JP7500438B2
(ja)
|
2018-06-01 |
2024-06-17 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
|
|
EP3836930A4
(en)
|
2018-08-16 |
2022-05-11 |
Beyondspring Pharmaceuticals Inc. |
Method and composition for stimulating immune response
|
|
JP2022513038A
(ja)
|
2018-11-14 |
2022-02-07 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
チューブリン結合薬を使用する癌の治療方法
|
|
CN112778155B
(zh)
|
2019-11-11 |
2023-08-11 |
大连万春布林医药有限公司 |
妥卡雷琐衍生物及其用途
|
|
MX2022013808A
(es)
|
2020-05-04 |
2023-02-09 |
Beyondspring Pharmaceuticals Inc |
Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad.
|